news
Study finds coronaviruses do not readily induce cross-protective antibody responses
Researchers have found that antibodies produced in response to SARS and COVID-19 are cross-reactive, but not cross protective in cells and mice.
List view / Grid view
Immunology
news
Lipid mediators suggested as potential COVID-19 inflammation treatment
A new article has outlined the body's inflammatory response to COVID-19 infection, saying that lipid mediators derived from omega-3 fatty acids could prevent life-threatening inflammation.
news
Adding RPL6 protein to vaccine prevents malaria in mice, find researchers
Researchers have shown that adding the RPL6 protein to malaria vaccines was successful at protecting mice against the condition.
news
Oxford University and NIH COVID-19 vaccine shows success in rhesus macaques
A vaccine currently in Phase I clinical trials was effective at inducing immune responses against SARS-CoV-2 in mice and rhesus macaques.
news
Combination of two neutralising antibodies suggested as COVID-19 treatment
Two antibodies named B38 and H4 could work as a COVID-19 therapeutic by neutralising the virus, say researchers in China.
article
Utilising an interleukin-12 plasmid: a novel COVID-19 vaccine
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
news
New class of antigen-presenting immune cell identified by researchers
A new kind of dendritic cell has been discovered by researchers and could play a role presenting antigens to other immune cells during respiratory virus infections.
news
Researchers develop promising MERS vaccine, with potential for COVID-19
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
news
Researchers identify monoclonal antibody to neutralise COVID-19
An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
article
Intravenous immunoglobulins, hyperimmunes and pandemic viruses
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
news
Tregs produced by mesenchymal stromal cells with novel technique
By culturing blood cells with mesenchymal stromal cells (MSCs), researchers induced the production of cells with the same functionality as Tregs.
news
Antibodies developed from llama show promise in fighting COVID-19
Engineering antibodies found in a llama, researchers have developed a potential COVID-19 therapy which they say can neutralise SARS-CoV-2.
article
Developing respiratory therapeutics for prophylaxis and treatment
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
news
Synthetic antibodies show efficacy against bunyaviruses, study finds
Having developed synthetic antibodies made of VHH complexes, researchers showed that these could be used to combat bunyaviruses successfully.
news
NIAID releases strategic plan, outlining COVID-19 research priorities
The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.